Drugs / Lutetium-177 PSMA-I&T
Lutetium-177 PSMA-I&T
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05383079 | Sep 2022 → Aug 2026 overdue | prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04291300 | May 2020 → Feb 2023 | adenoid cystic carcinoma, salivary duct carcinoma | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lutetium-177 PSMA-I&T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05383079 ↗ |
| Known as | 177Lu-PSMA-I&T | “Lutetium-177 [177Lu]Lu-PSMA-I&T (177Lu-PSMA-I&T) and the bone-seeking α-emitter radium-223 (223Ra) are established life-extending therapies” PMID 41119954 ↗ Oct 2025 |
| Known as | [177Lu]Lu-PSMA-I&T | “Lutetium-177 [177Lu]Lu-PSMA-I&T (177Lu-PSMA-I&T) and the bone-seeking α-emitter radium-223 (223Ra) are established life-extending therapies” PMID 41119954 ↗ Oct 2025 |
| Modality | Other / unclassified | “177Lu-PSMA Radioligand therapy” NCT04291300 ↗ |
| Route | Intravenous | “4 cycles of 7.4 GBq intravenously” NCT04291300 ↗ |